nivolumab + telaglenastat

Nivolumab + telaglenastat is an investigational combination therapy consisting of two agents:

• Nivolumab is a monoclonal antibody that targets programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to enhance the anti-tumor immune response.
• Telaglenastat (CB-839) is a small molecule inhibitor of glutaminase 1, targeting cancer cell metabolism by blocking glutamine utilization.
  This combination was studied in phase I/II clinical trials for patients with advanced solid tumors, including clear-cell renal cell carcinoma (ccRCC), melanoma, and non-small-cell lung cancer. The rationale for the combination stems from preclinical data suggesting that inhibiting tumor metabolism with telaglenastat may enhance the efficacy of immunotherapy by improving T cell function within the tumor microenvironment. Clinical studies found that this regimen was generally well tolerated but did not demonstrate consistent efficacy across different patient cohorts.